KCNA5
Potassium voltage-gated channel subfamily A member 5
As of the edition of 20 October 2026, KCNA5 (potassium voltage-gated channel subfamily A member 5, UniProt P22460) has 3 drugs tested at it and 4 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22460
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Nervous system
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vernakalant | Marketed | Phase 4 | none listed |
| Ajmaline | Marketed | Phase 4 | none listed |
| BMS-394136 | Went quiet | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Cipher Pharmaceuticals | Route B |
| Bristol Myers Squibb | Route A |
The other 2 companies at KCNA5
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at KCNA5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.